Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
Loading...
Official URL
Full text at PDC
Publication date
2021
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
PLOS
Citations
Exportar
Citation
González-Rincón, J., Garcia-Vela, J. A., Gómez, S., Fernández-Cuevas, B., Nova-Gurumeta, S., Pérez-Sanz, N., Alcoceba, M., González, M., Anguita, E., López-Jiménez, J., González-Barca, E., Yáñez, L., Pérez-Persona, E., de la Serna, J., Fernández-Zarzoso, M., Deben, G., Peñalver, F. J., Fernández, M. C., de Oteyza, J. P., Andreu, M. Á., … García-Marco, J. A. (2021). Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). PloS one, 16(9), e0257353. https://doi.org/10.1371/journal.pone.0257353
Abstract
Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1, SF3B1, ATM, TP53, BIRC3 and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM (rituximab en mantenimiento) clinical trial. The mutational status of our patients with CLL, except for the TP53 gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment.
Description
Plan Estatal de I+D+I 2008-2011
Plan Estatal de I+D+I 2013-2016